The observation of the up-regulation of multiple signaling pathways after treatment with FLT3i raised the possibility that FLT3-ITD AML cells could be sensitized to signals from external cytokines, thereby leading to the continued activation of signaling pathways that activate genes via AP-1 and RUNX1. The gene discussed is JUN; the disease is acute myeloid leukemia.